N/A N=122 Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
Asthma · Asthma in Children
Primary: Change in FeNO Value — -26.1 percent change — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=46 Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans
Healthy Volunteers
Primary: Virus Infection — 8; 18 Participants
N/A N=8 Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain
Neuropathy
Primary: Change in Pain Numerical Rating Scale (NRS) — 43.75 units on a scale
N/A N=319 Delivery Models of Caregiver Support and Education
Dementia
Primary: Revised Memory and Behavior Problems Checklist (Reaction Subscale) — 19.46; 14.31; 10.73 score on a scale — p=<0.001
Phase 2 N=92 Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Chemotherapy Induced Anemia
Primary: Maximum Change in Hb Within 16 Weeks From Baseline Without Red Blood Cell (RBC) Transfusion — 2.47 g/dL
N/A N=386 Trial of Overminus Spectacle Therapy for Intermittent Exotropia
Intermittent Exotropia
Primary: Mean Distance Control at 12-Months (On-Treatment Visit) — 1.8; 2.8 points
Phase 3 N=377 Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
Bipolar Depression
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -16.70; -12.12 score on a scale — p=<0.0001
N/A N=55 Renuvion Dermal System for Dermal Resurfacing
Wrinkle · Rhytides
Primary: Independent Photo Reviewer Fitzpatrick Wrinkle and Elastosis Scale (FWS) — 55 Participants — p=<.0001
Phase 2 N=25 An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Breast Cancer
Primary: Cohort A: Recommended Phase2 Dose (RP2D) — 400 mg
Phase 2 N=18 Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Phase 2 N=20 Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
Non Small Cell Lung Cancer
Primary: Overall Survival — 27.6; 12.7; NA months
N/A N=182 Intraosseous Versus Intravenous Vascular Access During Cardiac Arrest
Cardiac Arrest
Primary: First Attempt Success Rate Between the Tibial IO, Humeral IO, and Peripheral IV. — 26; 17; 58 Participants
Phase 2 N=31 A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
Type 1 Diabetes
Primary: Percentage of Time With Sensor Glucose Values Between 70 and 180 Milligrams Per Deciliter (mg/dL) With Continuous Glucose Monitoring (CGM) — 71.57; 65.76; 70.18…
Phase 4 N=20 CNS Study of Patients Switching From Tacrolimus to Envarsus
Renal Transplant Patients
Primary: Change in Quality of Life — 2.7; 1.35; 0.2 score on a scale
Phase 4 N=25 Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
Diabetes Mellitus, Type 1
Primary: Continuous Glucose Monitoring - Time in Range (70-140 mg/dl) — 36.3; 45.6; 37.2; 43.9 percentage of Time in Range 70-140mg/dL — p=<0.05